Market Newsdesk

TORONTO, March 19, 2026 (GLOBE NEWSWIRE) — BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE: BLK), today announced the March 2026 cash distributions for the iShares ETFs listed on the TSX or Cboe Canada which pay on a monthly or quarterly basis. Unitholders of record of the applicable iShares ETF on March 26, 2026 will receive cash distributions payable in respect of that iShares ETF on March 31, 2026.

Details regarding the “per unit” distribution amounts are as follows:

Fund Name	Fund Ticker	Cash Distribution Per Unit
iShares 1-10 Year Laddered Corporate Bond Index ETF	CBH	$0.050
iShares 1-5 Year Laddered Corporate Bond Index ETF	CBO	$0.053
iShares S&P/TSX Canadian Dividend Aristocrats Index ETF	CDZ	$0.117
iShares Equal Weight Banc & Lifeco ETF	CEW	$0.062
iShares Global Real Estate Index ETF	CGR	$0.155
iShares International Fundamental Index ETF	CIE	$0.064
iShares Global Infrastructure Index ETF	CIF	$0.325
iShares 1-5 Year Laddered Government Bond Index ETF	CLF	$0.033
iShares 1-10 Year Laddered Government Bond Index ETF	CLG	$0.037
iShares US Fundamental Index ETF	CLU	$0.172
iShares US Fundamental Index ETF	CLU.C	$0.211
iShares S&P/TSX Canadian Preferred Share Index ETF	CPD	$0.062
iShares Canadian Fundamental Index ETF	CRQ	$0.184
iShares US Dividend Growers Index ETF (CAD-Hedged)	CUD	$0.090
iShares Convertible Bond Index ETF	CVD	$0.075
iShares Global Water Index ETF	CWW	$0.209
iShares Global Monthly Dividend Index ETF (CAD-Hedged)	CYH	$0.072
iShares Canadian Financial Monthly Income ETF	FIE	$0.040
iShares ESG Balanced ETF Portfolio	GBAL	$0.239
iShares ESG Conservative Balanced ETF Portfolio	GCNS	$0.251
iShares ESG Equity ETF Portfolio	GEQT	$0.178
iShares ESG Growth ETF Portfolio	GGRO	$0.217
iShares U.S. Aggregate Bond Index ETF	XAGG	$0.120
iShares U.S. Aggregate Bond Index ETF(1)	XAGG.U	$0.087
iShares U.S. Aggregate Bond Index ETF (CAD-Hedged)	XAGH	$0.101
iShares Core Balanced ETF Portfolio	XBAL	$0.155
iShares Core Canadian Universe Bond Index ETF	XBB	$0.080
iShares Core Canadian Corporate Bond Index ETF	XCB	$0.070
iShares ESG Advanced Canadian Corporate Bond Index ETF	XCBG	$0.125
iShares U.S. IG Corporate Bond Index ETF	XCBU	$0.121
iShares U.S. IG Corporate Bond Index ETF(1)	XCBU.U	$0.087
iShares Canadian Growth Index ETF	XCG	$0.107
iShares Core Conservative Balanced ETF Portfolio	XCNS	$0.155
iShares S&P/TSX SmallCap Index ETF	XCS	$0.091
iShares ESG Advanced MSCI Canada Index ETF	XCSR	$0.469
iShares Canadian Value Index ETF	XCV	$0.376
iShares Core MSCI Global Quality Dividend Index ETF	XDG	$0.074
iShares Core MSCI Global Quality Dividend Index ETF(1)	XDG.U	$0.053
iShares Core MSCI Global Quality Dividend Index ETF (CAD-Hedged)	XDGH	$0.072
iShares Core MSCI Canadian Quality Dividend Index ETF	XDIV	$0.119
iShares Core MSCI US Quality Dividend Index ETF	XDU	$0.066
iShares Core MSCI US Quality Dividend Index ETF(1)	XDU.U	$0.048
iShares Core MSCI US Quality Dividend Index ETF (CAD-Hedged)	XDUH	$0.059
iShares Canadian Select Dividend Index ETF	XDV	$0.111
iShares J.P. Morgan USD Emerging Markets Bond Index ETF (CAD-Hedged)	XEB	$0.055
iShares S&P/TSX Capped Energy Index ETF	XEG	$0.167
iShares S&P/TSX Composite High Dividend Index ETF	XEI	$0.112
iShares Jantzi Social Index ETF	XEN	$0.225
iShares Core Equity ETF Portfolio	XEQT	$0.091
iShares ESG Aware MSCI Canada Index ETF	XESG	$0.200
iShares Core Canadian 15+ Year Federal Bond Index ETF	XFLB	$0.115
iShares Flexible Monthly Income ETF	XFLI	$0.174
iShares Flexible Monthly Income ETF(1)	XFLI.U	$0.127
iShares Flexible Monthly Income ETF (CAD-Hedged)	XFLX	$0.168
iShares S&P/TSX Capped Financials Index ETF	XFN	$0.147
iShares Floating Rate Index ETF	XFR	$0.040
iShares Core Canadian Government Bond Index ETF	XGB	$0.050
iShares Global Government Bond Index ETF (CAD-Hedged)	XGGB	$0.042
iShares Core Growth ETF Portfolio	XGRO	$0.117
iShares Canadian HYBrid Corporate Bond Index ETF	XHB	$0.076
iShares U.S. High Dividend Equity Index ETF (CAD-Hedged)	XHD	$0.084
iShares U.S. High Dividend Equity Index ETF	XHU	$0.078
iShares U.S. High Yield Bond Index ETF (CAD-Hedged)	XHY	$0.083
iShares Core S&P/TSX Capped Composite Index ETF	XIC	$0.272
iShares U.S. IG Corporate Bond Index ETF (CAD-Hedged)	XIG	$0.068
iShares 1-5 Year U.S. IG Corporate Bond Index ETF (CAD-Hedged)	XIGS	$0.142
iShares Core Income Balanced ETF Portfolio	XINC	$0.159
iShares Core Canadian Long Term Bond Index ETF	XLB	$0.062
iShares S&P/TSX Capped Materials Index ETF	XMA	$0.037
iShares S&P/TSX Completion Index ETF	XMD	$0.149
iShares MSCI Min Vol USA Index ETF (CAD-Hedged)	XMS	$0.145
iShares MSCI USA Momentum Factor Index ETF	XMTM	$0.035
iShares MSCI Min Vol USA Index ETF	XMU	$0.297
iShares MSCI Min Vol USA Index ETF(1)	XMU.U	$0.217
iShares MSCI Min Vol Canada Index ETF	XMV	$0.329
iShares S&P/TSX North American Preferred Stock Index ETF (CAD-Hedged)	XPF	$0.073
iShares High Quality Canadian Bond Index ETF	XQB	$0.054
iShares MSCI USA Quality Factor Index ETF	XQLT	$0.061
iShares S&P/TSX Capped REIT Index ETF	XRE	$0.060
iShares ESG Aware Canadian Aggregate Bond Index ETF	XSAB	$0.049
iShares Core Canadian Short Term Bond Index ETF	XSB	$0.069
iShares Conservative Short Term Strategic Fixed Income ETF	XSC	$0.053
iShares Conservative Strategic Fixed Income ETF	XSE	$0.053
iShares Core Canadian Short Term Corporate Bond Index ETF	XSH	$0.063
iShares ESG Advanced 1-5 Year Canadian Corporate Bond Index ETF	XSHG	$0.124
iShares 1-5 Year U.S. IG Corporate Bond Index ETF	XSHU	$0.146
iShares 1-5 Year U.S. IG Corporate Bond Index ETF(1)	XSHU.U	$0.105
iShares Short Term Strategic Fixed Income ETF	XSI	$0.057
iShares Core Canadian Short-Mid Term Universe Bond Index ETF	XSMB	$0.102
iShares S&P/TSX Capped Consumer Staples Index ETF	XST	$0.144
iShares ESG Aware Canadian Short Term Bond Index ETF	XSTB	$0.047
iShares 0-5 Year TIPS Bond Index ETF (CAD-Hedged)	XSTH	$0.000
iShares 0-5 Year TIPS Bond Index ETF	XSTP	$0.000
iShares 0-5 Year TIPS Bond Index ETF(1)	XSTP.U	$0.000
iShares ESG Aware MSCI USA Index ETF	XSUS	$0.085
iShares 20+ Year U.S. Treasury Bond Index ETF (CAD-Hedged)	XTLH	$0.121
iShares 20+ Year U.S. Treasury Bond Index ETF	XTLT	$0.123
iShares 20+ Year U.S. Treasury Bond Index ETF(1)	XTLT.U	$0.089
iShares Core S&P Total U.S. Stock Market Index ETF (CAD-Hedged)	XTOH	$0.080
iShares Core S&P Total U.S. Stock Market Index ETF	XTOT	$0.070
iShares Core S&P Total U.S. Stock Market Index ETF(1)	XTOT.U	$0.051
iShares Diversified Monthly Income ETF	XTR	$0.040
iShares Core S&P U.S. Total Market Index ETF (CAD-Hedged)	XUH	$0.103
iShares S&P U.S. Financials Index ETF	XUSF	$0.237
iShares ESG Advanced MSCI USA Index ETF	XUSR	$0.189
iShares S&P/TSX Capped Utilities Index ETF	XUT	$0.092
iShares Core S&P U.S. Total Market Index ETF	XUU	$0.127
iShares Core S&P U.S. Total Market Index ETF(1)	XUU.U	$0.093
iShares MSCI USA Value Factor Index ETF	XVLU	$0.123

^(1
) Distribution per unit amounts are in U.S. dollars for XAGG.U, XCBU.U, XDG.U, XDU.U, XFLI.U, XMU.U, XSHU.U, XSTP.U, XTLT.U, XTOT.U, and XUU.U

Estimated March Cash Distributions for the iShares Premium Money Market ETF

The March cash distributions per unit for the iShares Premium Money Market ETF are estimated to be as follows:

Fund Name	Fund Ticker	Estimated Cash Distribution Per Unit
iShares Premium Money Market ETF	CMR	$0.095

BlackRock Canada expects to issue a press release on or about March 25, 2026, which will provide the final amounts for the iShares Premium Money Market ETF.

Further information on the iShares ETFs can be found at http://www.blackrock.com/ca.

About BlackRock

BlackRock’s purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit www.blackrock.com/corporate.

About iShares ETFs

iShares unlocks opportunity across markets to meet the evolving needs of investors. With more than twenty years of experience, a global line-up of more than 1,700 exchange traded funds (ETFs) and approximately $5.47 trillion in assets under management as of December 31, 2025, iShares continues to drive progress for the financial industry. iShares funds are powered by the expert portfolio and risk management of BlackRock.   

iShares^® ETFs are managed by BlackRock Canada.

Commissions, trailing commissions, management fees and expenses all may be associated with investing in iShares ETFs. Please read the relevant prospectus before investing. The funds are not guaranteed, their values change frequently and past performance may not be repeated. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional.

Standard & Poor’s® and S&P® are registered trademarks of Standard & Poor’s Financial Services LLC (“S&P”). Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC (“Dow Jones”). TSX is a registered trademark of TSX Inc. (“TSX”). All of the foregoing trademarks have been licensed to S&P Dow Jones Indices LLC and sublicensed for certain purposes to BlackRock Fund Advisors (“BFA”),  which in turn has sub-licensed these marks to its affiliate, BlackRock Asset Management Canada Limited (“BlackRock Canada”), on behalf of the applicable fund(s). The index is a product of S&P Dow Jones Indices LLC, and has been licensed for use by BFA and by extension, BlackRock Canada and the applicable fund(s). The funds are not sponsored, endorsed, sold or promoted by S&P Dow Jones Indices LLC, Dow Jones, S&P, any of their respective affiliates (collectively known as “S&P Dow Jones Indices”) or TSX, or any of their respective affiliates. Neither S&P Dow Jones Indices nor TSX make any representations regarding the advisability of investing in such funds.

MSCI is a trademark of MSCI, Inc. (“MSCI”). The ETF is permitted to use the MSCI mark pursuant to a license agreement between MSCI and BlackRock Institutional Trust Company, N.A., relating to, among other things, the license granted to BlackRock Institutional Trust Company, N.A. to use the Index. BlackRock Institutional Trust Company, N.A. has sublicensed the use of this trademark to BlackRock. The ETF is not sponsored, endorsed, sold or promoted by MSCI and MSCI makes no representation, condition or warranty regarding the advisability of investing in the ETF.

Contact for Media:

Sydney Punchard
Email: [email protected]

• Slovakia becomes WeRide’s fourth European market after France, Belgium, and Switzerland.
• WeRide enters Slovakia via a landmark partnership with ELEVATE Slovakia, an initiative bringing together the Ministry of Transport of the Slovak Republic, City of Bratislava, Slovak Post, academic institutions, and private companies to deploy WeRide’s multi-product autonomous vehicle (AV) portfolio.
• Testing will start in capital Bratislava in the first half of 2026, before expanding to Košice and the High Tatras resort area, paving the way for fully driverless commercial operations.

BRATISLAVA, Slovakia, March 19, 2026 (GLOBE NEWSWIRE) — WeRide (NASDAQ: WRD, HKEX: 0800), a global leader in autonomous driving technology, today announced its entry into Slovakia through a strategic partnership with ELEVATE Slovakia to deploy autonomous vehicles (AVs), launching the country’s first AV program. This national-level rollout represents Europe’s first large-scale, multi-product autonomous driving commercial deployment. The move marks WeRide’s fourth European market after France, Belgium, and Switzerland, expanding its global footprint to over 40 cities across12 countries.

ELEVATE Slovakia is a national, multi-stakeholder initiative that brings together public sector partners such as the Ministry of Transport of the Slovak Republic; Ministry of Investments, Regional Development and Informatization of the Slovak Republic; the City of Bratislava; Slovak Post; academia and private companies. It aims to establish a safe, regulatory-ready framework for autonomous mobility, with the long-term objective of enabling nationwide fully driverless commercial operations.

WeRide will deploy its multi-product portfolio in Slovakia – including the Robotaxi, Robobus, Robovan, and Robosweeper – to support autonomous passenger mobility with the Ministry of Transport of the Slovak Republic, parcel logistics automation with Slovak Post, and smart sanitation operations with municipal partners such as the City of Bratislava. The first WeRide AVs are expected to arrive in Slovakia in spring 2026, with testing scheduled to start in the first half of 2026 in Bratislava, followed by expansion to Košice and the High Tatras. All testing will be conducted under Ministry of Transport supervision to ensure compliance with Slovak and European regulations, paving the way for fully driverless commercial operations once all legislative and safety requirements have been met.

“I view the signing of this agreement as the beginning of a process that will allow Slovakia to responsibly and in a controlled manner test autonomous technologies in transport. It will enable us to verify technologies transparently, with the participation of the state and with an emphasis on the public interest,” said Minister of Transport Jozef Ráž.

“WeRide’s global expansion is picking up speed as more governments and cities advance large-scale autonomous mobility. With plans for over 2,600 active Robotaxis by the end of 2026 and tens of thousands globally by 2030, Slovakia represents a strategic next step as we extend our global presence to 12 countries. By engaging early with governments, we aim to be their go-to partner and set the standards for safe, scalable AV commercialization,” said Dr. Tony Han, Founder and CEO of WeRide.

Under the agreement with ELEVATE Slovakia, WeRide will serve as the autonomous driving technology provider, while Slovak technology company DiusAi will act as the technological and implementation partner responsible for system integration and local operational support.

“Cooperation with WeRide is our first step toward ensuring that Slovakia does not merely adopt these technologies from abroad, but is able to actively test them, professionally evaluate them, and gradually integrate them into its own environment. We are aware that the path toward autonomous transport requires time, extensive testing, open expert discussion, and gradual adjustments to the legislative framework. This is precisely why we consider the ELEVATE Slovakia initiative to be key,” said DiusAi CEO Patrik Tkáč.

“Testing autonomous technologies represents an interesting opportunity for companies as well as for the creation of new jobs in the field of AI and innovation. Moreover, this opportunity can provide us with real data and experience that can be used in urban transport planning,” said Bratislava’s Chief City Strategist Ján Mazúr.

About WeRide

WeRide is a global leader and a first mover in the autonomous driving industry, as well as the first publicly traded Robotaxi company. Our autonomous vehicles have been tested or operated in over 40 cities across 12 countries. We are also the first and only technology company whose products have received autonomous driving permits in eight markets: China, the UAE, Singapore, France, Switzerland, Saudi Arabia, Belgium, and the US. Empowered by the smart, versatile, cost-effective, and highly adaptable WeRide One platform, WeRide provides autonomous driving products and services from L2 to L4, addressing transportation needs in the mobility, logistics, and sanitation industries. WeRide was named to Fortune’s 2025 Change the World and 2025 Future 50 lists.

https://www.weride.ai

About ELEVATE Slovakia

The ELEVATE Slovakia initiative serves as a long-term coordinating platform for the development of autonomous mobility in Slovakia. It brings together public institutions, academia, and the private sector with the goal of creating a safe, innovative, and regulatorily sustainable environment for the research, testing, and deployment of autonomous technologies.

https://elevateslovakia.com

About DiusAI

DiusAi is a Slovak technology company focused on the research, development, and deployment of advanced artificial intelligence solutions. At DiusAi, the team believes that technology should learn from people, not control them, and therefore creates AI that understands users, their needs, and their way of thinking. The company’s flagship product currently under development is Jarvis—a personal AI assistant that listens, understands, and learns from the user, with a strong emphasis on privacy, personalization, and secure adaptation to individual needs.

https://dius.ai/sk

Media Contacts

WeRide:

Email: [email protected]

Ministry of Transport of the Slovak Republic:

Email: [email protected]

DiusAI:

Email: [email protected]

Mobile: +421 911 718 259

Safe Harbor Statement

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to,” and similar statements. Statements that are not historical facts, including statements about WeRide’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in WeRide’s filings with the U.S. Securities and Exchange Commission and announcements on the website of the Hong Kong Stock Exchange. All information provided in this press release is as of the date of this press release. WeRide does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/116066ea-64a8-4e61-bddf-ea93b10ebae9

• Highly comparable biodistribution profiles of Radio-DARPin candidates labeled with imaging isotopes 
  
  ¹⁷⁷
  
  Lu or
  
  ²⁰³
  
  Pb allows for rapid expansion of pipeline with multiple therapeutic isotopes
  

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 19, 2026 (GLOBE NEWSWIRE) — Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will hold an oral presentation outlining new preclinical data on Radio-DARPins at the 3rd Global Radiopharmaceuticals Development Summit, taking place in Shanghai, China on March 19–20, 2026.

The presentation will outline the Radio-DARPins’ suitability to different isotopes with data on two Radio-DARPin candidates, each specific for a different tumor target. The results of studies in tumor-bearing mice show highly comparable biodistribution profiles for both Radio-DARPin candidates labeled with Lutetium-177 (¹⁷⁷Lu) or with Lead-203 (²⁰³Pb), with similar uptake and washout rates. Imaging with ¹⁷⁷Lu can be indicative of behavior with the therapeutic isotope Actinium-225 (²²⁵Ac), and similarly with ²⁰³Pb for ²¹²Pb.

“Our recent data confirms that our Radio-DARPin-vector design allows interchangeability of alpha-isotopes, including ²¹²Pb and ²²⁵Ac,” said Patrick Amstutz, Ph.D., CEO of Molecular Partners. “This feature offers us the opportunity and flexibility to evaluate Radio-DARPin candidates in an isotope-agnostic manner and to choose the most suitable therapeutic isotope, as late as with initial clinical data, without having to restart the entire drug discovery and development process – a significant advantage to tailor our candidates to patient needs.”

Details of the presentation

DARPins for targeted alpha therapy: from promising MP0712 first in-human data to opportunities for next Radio-DARPin candidates

Presenter: Daniel Steiner, Ph.D., SVP of Technology and Research
Time: 9:25 am CST, Friday, March 20
Location: Meeting Room B – IND Filing and Clinical Development Progress

The full presentation can be found here.

MP0712, Molecular Partners’ DLL3-targeted ²¹²Pb-based Radio-DARPin candidate co-developed with strategic partner Orano Med, is in an ongoing Phase 1/2a trial in the US (NCT07278479). Imaging data of MP0712 carrying the diagnostic isotope ²⁰³Pb under compassionate care are supportive of clinical development plans of MP0712 carrying the therapeutic isotope ²¹²Pb for patients with small cell lung cancer (SCLC) and other DLL3-expressing neuroendocrine cancers.

In February 2026, Molecular Partners entered into an agreement with Eckert & Ziegler, leading specialist in isotope-related components for nuclear medicine and radiation therapy, to enable the development and manufacturing of Radio-DARPin therapeutics. Eckert & Ziegler will support Molecular Partners with a comprehensive range of services covering development activities for Radio-DARPins with ²²⁵Ac as therapeutic payload and ¹⁷⁷Lu as imaging payload.

About Radio-DARPins

Molecular Partners’ Radio-DARPins are designed as ideal vectors for precise delivery of potent alpha-emitting isotopes to tumor lesions and have the potential to unlock a broad range of tumor targets for targeted radiopharmaceuticals. Building on the DARPins’ unique properties, Molecular Partners has developed a proprietary Radio-DARPin platform to address historic limitations of radioligand therapy, such as kidney accumulation and toxicity, and suboptimal tumor uptake. Molecular Partners’ Radio-DARPins addresses these limitations through half-life extension technologies and surface engineering approaches, while preserving the advantages of the small protein format.

About DARPin Therapeutics

DARPin (Designed Ankyrin Repeat Protein) therapeutics are a novel class of protein drugs based on natural binding proteins, which have been clinically validated across several therapeutic areas and developed through to the registrational stage. The key properties of DARPins – intrinsic high affinity and specificity, small size, flexible architecture, and high stability – offer unmatched advantages to drug design, such as multispecificity, broad target range, and tunable half-life. The Company’s Radio-DARPins enable highly effective and specific delivery of potent radioactive payloads to tumor lesions while sparing healthy tissues. Molecular Partners’ Switch-DARPins allow conditional, tumor-localized immune activation, which enables increased safety and potency for next-generation immune cell engagers. Powered by twenty years of DARPin leadership in the clinic, Molecular Partners has built an innovative, rapid and cost-effective DARPin drug design engine, including proprietary DARPin libraries and platforms, for candidates produced with optimized properties and tailored to therapeutic needs.

About Molecular Partners AG 
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of protein drugs known as DARPin therapeutics, for medical challenges other treatment modalities cannot readily address. Molecular Partners leverages the key properties of DARPins to design and develop differentiated therapeutics for cancer patients, including targeted radiopharmaceuticals and next-generation immune cell engagers. The Company has proprietary programs in various stages of pre-clinical and clinical development, as well as programs developed through partnerships with leading pharmaceutical companies and academic centers. Molecular Partners, founded in 2004, has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit www.molecularpartners.com and find us on LinkedIn and Twitter / X @MolecularPrtnrs

For further details, please contact:

Seth Lewis, EVP Corporate Finance
Concord, Massachusetts, U.S.
[email protected]
Tel: +1 781 420 2361

Laura Jeanbart, Ph.D., Head of Portfolio Management & Communications 
Zurich-Schlieren, Switzerland
[email protected]
Tel: +41 44 575 19 35

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners’ current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners’ product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners’ collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; the expected benefits of the strategic review; and Molecular Partners’ expected business and financial outlook, including anticipated expenses and cash utilization for 2026 and its expectation of its current cash runway. These statements may be identified by words such as “aim”, “anticipate”, “expect”, “guidance”, “intend”, “outlook”, “plan”, “potential”, “will” and similar expressions, and are based on Molecular Partners’ current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners’ expectations include, but are not limited to, those set forth in under the heading “Risk Factors” in Molecular Partners’ Annual Report on Form 20-F for the year ended December 31, 2025 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners’ website at www.molecularpartners.com. In addition, this press release contains information relating to interim data as of the relevant data cutoff date, results of which may differ from topline results that may be obtained in the future.

Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

SHENZHEN, China, March 19, 2026 (GLOBE NEWSWIRE) — LexinFintech Holdings Ltd. (“Lexin” or the “Company”) (NASDAQ: LX), a leading technology-empowered personal financial service enabler in China, today announced its unaudited financial results for the quarter ended December 31, 2025.

Mr. Jay Wenjie Xiao, Chairman and Chief Executive Officer of Lexin, commented, “The fourth quarter marked an important transition for us as we adapted to the new regulatory framework. Amid heightened industry risk volatility, our proactive compliance efforts and disciplined risk management enabled us to secure a stable transition, while balancing business scale and overall asset quality.

Despite the complex macro environment in the fourth quarter, we concluded 2025 with robust full-year results. For the full year of 2025, net profit stood at RMB1.7 billion, representing a year-over-year increase of 52.4%. These results underscore the fundamental resilience and diversity of our unique business ecosystem.

Going forward, we believe that the market will continue to consolidate toward leading, compliant platforms with prudent risk management. Leveraging our unique business ecosystem, we are well-positioned to capture potential opportunities as the industry enters this new stage of high-quality development.

We also remain deeply committed to enhancing shareholder returns. In accordance with our dividend policy, our board of directors has approved a dividend of US$0.188 per ADS, representing 30% of net income from the second half of 2025. In addition to cash dividends, we have cumulatively repurchased US$39 million worth of ADSs as of the date of this announcement. Furthermore, my personal US$10 million share purchase plan has been fully implemented. We will continue to explore various avenues to deliver sustainable value to our shareholders.”

Mr. James Zheng, Chief Financial Officer of Lexin, commented, “During the fourth quarter, as we navigated elevated risk volatility and the evolving regulatory landscape, our proactive risk management and pricing adjustments weighed on our bottom line, with net income recording RMB214 million. The resilience of our diversified business ecosystem provided an effective counterbalance to this impact. In parallel, we fortified our balance sheet with ample provisioning, while our funding costs declined substantially. These actions have fundamentally strengthened our foundation for long-term growth.

Looking ahead to 2026, as the industry enters a new phase of normalization, we will leverage our unique business ecosystem and comprehensive product matrix to continue executing our disciplined strategy, and deliver sustainable, long-term returns to our shareholders.”

Fourth Quarter and Full Year 2025 Operational Highlights:

User Base

• Total number of registered users across our platform reached 245 million as of December 31, 2025, representing an increase of 7.6% from 228 million as of December 31, 2024.
• Number of active users¹ in the fourth quarter of 2025 was 4.5 million, representing a decrease of 3.8% from 4.7 million in the fourth quarter of 2024. Number of active users¹ in 2025 was 8.2 million, representing an increase of 0.3% from 8.2 million in 2024.
• Number of cumulative borrowers with successful drawdown was 36.7 million as of December 31, 2025, an increase of 8.9% from 33.8 million as of December 31, 2024.

Loan Facilitation Business

• As of December 31, 2025, we cumulatively originated RMB1,530.5 billion in loans, an increase of 15.5% from RMB1,325.1 billion as of December 31, 2024.

• Total loan originations² in the fourth quarter of 2025 was RMB50.0 billion, a decrease of 3.8% from RMB52.0 billion in the fourth quarter of 2024. Total loan originations² in 2025 was RMB205 billion, a decrease of 3.2% from RMB212 billion in 2024.
• Total outstanding principal balance of loans³ was RMB96.6 billion as of December 31, 2025, representing a decrease of 12.4% from RMB110 billion as of December 31, 2024.

Credit Performance

⁴

• 90 day+ delinquency ratio⁵ was 3.1% as of December 31, 2025, as compared with 3.0% as of September 30, 2025.
• First payment default rate (30 day+) for new loan originations was below 1% as of December 31, 2025.

Installment E-commerce Platform Service

• GMV⁶ in the fourth quarter of 2025 for our installment e-commerce platform service was RMB2,154 million, representing an increase of 122% from RMB969 million in the fourth quarter of 2024. GMV⁶ in 2025 for our installment e-commerce platform service was RMB7,622 million, representing an increase of 110% from RMB3,633 million in 2024.
• In the fourth quarter of 2025, our installment e-commerce platform service served over 480,000 users.

Other Operational Highlights

• The weighted average tenor of loans originated in the fourth quarter of 2025 was approximately 11.9 months, as compared with 13.1 months in the fourth quarter of 2024. The weighted average tenor of loans originated on our platform in 2025 was approximately 12.9 months, as compared with 12.9 months in 2024.
• Repeated borrowers’ contribution⁷ of loans across our platform for the fourth quarter of 2025 was 88.3%. Repeated borrowers’ contribution⁷ of loans across our platform for 2025 was 86.4%.

Fourth Quarter 2025
Financial Highlights:

• Total operating revenue was RMB3,043 million, representing a decrease of 16.8% from the fourth quarter of 2024.
• Credit facilitation service income was RMB2,485 million, representing a decrease of 8.4% from the fourth quarter of 2024. Tech-empowerment service income was RMB170 million, representing a decrease of 71.7% from the fourth quarter of 2024. Installment e-commerce platform service income was RMB388 million, representing an increase of 12.5% from the fourth quarter of 2024.
• Net income attributable to ordinary shareholders of the Company was RMB214 million, representing a decrease of 41.0% from the fourth quarter of 2024. Net income per ADS attributable to ordinary shareholders of the Company was RMB1.24 on a fully diluted basis.
• Adjusted net income attributable to ordinary shareholders of the Company⁸ was RMB239 million, representing a decrease of 38.9% from the fourth quarter of 2024. Adjusted net income per ADS attributable to ordinary shareholders of the Company⁸ was RMB1.38 on a fully diluted basis.

Full Year 2025
Financial Highlights:

• Total operating revenue was RMB13,152 million, representing a decrease of 7.4% from 2024.
• Credit facilitation service income was RMB9,562 million, representing a decrease of 13.1% from 2024. Tech-empowerment service income was RMB2,081 million, representing an increase of 10.6% from 2024. Installment e-commerce platform service income was RMB1,509 million, representing an increase of 14.1% from 2024.
• Net income attributable to ordinary shareholders of the Company was RMB1,677 million, representing an increase of 52.4% from 2024. Net income per ADS attributable to ordinary shareholders of the Company was RMB9.45 on a fully diluted basis.
• Adjusted net income attributable to ordinary shareholders of the Company⁸ was RMB1,795 million, representing an increase of 49.2% from 2024. Adjusted net income per ADS attributable to ordinary shareholders of the Company⁸ was RMB10.11 on a fully diluted basis.

__________________________

1. Active users refer to, for a specified period, users who made at least one transaction during that period through our platform or through our third-party partners’ platforms using the credit line granted by us.
2. Total loan originations refer to the total principal amount of loans originated during the given period through our platform or through our third-party partners’ platforms.
3. Total outstanding principal balance of loans refers to the total amount of principal outstanding for loans facilitated and originated at the end of each period, including loans guaranteed by our financial guarantee companies and the loans facilitated across third party platforms that we bear principal risk and excluding loans delinquent for more than 180 days that are charged-off.
4. Loans under Intelligent Credit Platform are excluded from the calculation of credit performance. Intelligent Credit Platform (ICP) is an intelligent platform on our “Fenqile” app, under which we match borrowers and financial institutions through big data and cloud computing technology. For loans facilitated through ICP, the Company does not bear principal risk.
5. “90 day+ delinquency rate” refers to the outstanding principal balance of on- and off-balance sheet loans that were 91 to 180 calendar days past due as a percentage of the total outstanding principal balance of on- and off-balance sheet loans across our platform and those loans across third party platforms that we bear principle risk as of a specific date. Loans that are charged-off and loans under “ICP”, E-commerce business and overseas are not included in the delinquency rate calculation.
6. GMV refers to the total value of transactions completed for products purchased on our e-commerce and Maiya channel, net of returns.
7. Repeated borrowers’ contribution for a given period refers to the principal amount of loans borrowed during that period by borrowers who had previously made at least one successful drawdown as a percentage of the total loan facilitation and origination volume through our platform during that period.
8. Adjusted net income attributable to ordinary shareholders of the Company, adjusted net income per ordinary share and per ADS attributable to ordinary shareholders of the Company are non-GAAP financial measures. For more information on non-GAAP financial measures, please see the section of “Use of Non-GAAP Financial Measures Statement” and the tables captioned “Unaudited Reconciliations of GAAP and Non-GAAP Results” set forth at the end of this press release.

Fourth Quarter
2025 Financial Results:

Operating revenue was RMB3,043 million in the fourth quarter of 2025, as compared to RMB3,659 million in the fourth quarter of 2024.

Credit facilitation service income was RMB2,485 million in the fourth quarter of 2025, as compared to RMB2,712 million in the fourth quarter of 2024. The decrease was due to the decrease in loan facilitation and servicing fees-credit oriented and financing income, partially offset by the increases in guarantee income.

Loan facilitation and servicing fees-credit oriented was RMB1,293 million in the fourth quarter of 2025, as compared to RMB1,624 million in the fourth quarter of 2024. The decrease was primarily due to the decrease in the APR of off-balance sheet loans and the decrease in origination of off-balance sheet loans.

Guarantee income was RMB685 million in the fourth quarter of 2025, as compared to RMB577 million in the fourth quarter of 2024. The increase was primarily due to the increase of outstanding balances in the off-balance sheet loans funded by certain institutional funding partners, which are accounted for under ASC 460, Guarantees.

Financing income was RMB506 million in the fourth quarter of 2025, as compared to RMB510 million in the fourth quarter of 2024.

Tech-empowerment service income was RMB170 million in the fourth quarter of 2025, as compared to RMB602 million in the fourth quarter of 2024. The decrease was primarily due to the decrease of loan facilitation volume through ICP.

Installment e-commerce platform service income was RMB388 million in the fourth quarter of 2025, as compared to RMB345 million in the fourth quarter of 2024. The increase was primarily driven by the increase in transaction volume with third-party sellers.

Cost of sales consisted of cost of inventory sold and other costs. Cost of sales was RMB248 million in the fourth quarter of 2025, as compared to RMB353 million in the fourth quarter of 2024. The decrease was primarily driven by the decrease in transaction volume of online direct sales which is recorded on a gross basis.

Funding cost was RMB34.2 million in the fourth quarter of 2025, as compared to RMB57.5 million in the fourth quarter of 2024. The decrease was primarily driven by the decrease in funding rates and balance of funding debts to fund the on-balance sheet loans.

Processing and servicing costs was RMB633 million in the fourth quarter of 2025, as compared to RMB583 million in the fourth quarter of 2024. The increase was primarily due to the increase in risk management expenses.

Provision for financing receivables was RMB250 million in the fourth quarter of 2025, as compared to RMB297 million in the fourth quarter of 2024. The decrease was primarily driven by the increase in performance of oversea business, offset by the increase in the outstanding loan balances of on-balance sheet loans.

Provision for contract assets and receivables was RMB159 million in the fourth quarter of 2025, as compared to RMB154 million in the fourth quarter of 2024.

Provision for contingent guarantee liabilities was RMB935 million in the fourth quarter of 2025, as compared to RMB941 million in the fourth quarter of 2024.

Gross profit was RMB784 million in the fourth quarter of 2025, as compared to RMB1,274 million in the fourth quarter of 2024.

Sales and marketing expenses was RMB388 million in the fourth quarter of 2025, as compared to RMB464 million in the fourth quarter of 2024. The decrease was primarily driven by the decrease in personnel-related costs.

Research and development expenses was RMB132 million in the fourth quarter of 2025, as compared to RMB151 million in the fourth quarter of 2024. The decrease was primarily due to the decrease in personnel-related costs.

General and administrative expenses was RMB70.0 million in the fourth quarter of 2025, as compared to RMB95.3 million in the fourth quarter of 2024. The decrease was primarily driven by the decrease in personnel-related costs.

Change in fair value of financial guarantee derivatives and loans at fair value was a gain of RMB79.4 million in the fourth quarter of 2025, as compared to a loss of RMB144 million in the fourth quarter of 2024. The change was primarily driven by the fair value gains realized as a result of the release of guarantee obligation as loans are repaid, partially offset by the fair value loss from the re-measurement of the expected loss rates.

Income tax expense was RMB51.9 million in the fourth quarter of 2025, as compared to RMB67.6 million in the fourth quarter of 2024. The decrease was primarily due to the decrease in income before income tax expense.

Net income was RMB214 million in the fourth quarter of 2025, as compared to RMB363 million in the fourth quarter of 2024.

Full Year
2025 Financial Results:

Operating revenue was RMB13,152 million in 2025, as compared to RMB14,204 million in 2024.

Credit facilitation service income was RMB9,562 million in 2025, as compared to RMB11,000 million in 2024. The decrease was due to the decrease in loan facilitation and servicing fees-credit oriented and guarantee income, partially offset by the increases in financing income.

Loan facilitation and servicing fees-credit oriented was RMB4,989 million in 2025, as compared to RMB6,326 million in 2024. The decrease was primarily due to the decrease in the APR of off-balance sheet loans and the decrease in origination of off-balance sheet loans.

Guarantee income was RMB2,424 million in 2025, as compared to RMB2,664 million in 2024. The decrease was primarily due to the decrease of annual average outstanding balances in the off-balance sheet loans funded by certain institutional funding partners, which are accounted for under ASC 460, Guarantees.

Financing income was RMB2,150 million in 2025, as compared to RMB2,010 million in 2024. The increase was primarily driven by the increase in the outstanding balances of on-balance sheet loans.

Tech-empowerment service income was RMB2,081 million in 2025, as compared to RMB1,881 million in 2024. The increase was primarily driven by the increase in referral services.

Installment e-commerce platform service income was RMB1,509 million in 2025, as compared to RMB1,322 million in 2024. The increase was primarily driven by the increase in transaction volume with third-party sellers.

Cost of sales consisted of cost of inventory sold and other costs. Cost of sales was RMB1,206 million in 2025, as compared to RMB1,320 million in 2024. The decrease was primarily driven by the decrease in transaction volume of online direct sales which is recorded on a gross basis.

Funding cost was RMB229 million in 2025, as compared to RMB326 million in 2024. The decrease was primarily driven by the decrease in funding rates and balance of funding debts to fund the on-balance sheet loans.

Processing and servicing costs was RMB2,443 million in 2025, as compared to RMB2,292 million in 2024. The increase was primarily driven by the increase in risk management expenses.

Provision for financing receivables was RMB1,017 million in 2025, as compared to RMB866 million in 2024. The increase was primarily due to the increase in the outstanding loan balances of on-balance sheet loans.

Provision for contract assets and receivables was RMB614 million in 2025, as compared to RMB718 million in 2024. The decrease was primarily driven by the decrease of the outstanding loan balances of off-balance sheet loans.

Provision for contingent guarantee liabilities was RMB3,175 million in 2025, as compared to RMB3,656 million in 2024. The decrease was primarily due to the decrease of outstanding balances in the off-balance sheet loans funded by certain institutional funding partners, which are accounted for under ASC 460, Guarantees.

Gross profit was RMB4,469 million in 2025, as compared to RMB5,026 million in 2024.

Sales and marketing expenses was RMB1,919 million in 2025, as compared to RMB1,787 million in 2024. The increase was primarily driven by the increase in online advertising costs.

Research and development expenses was RMB595 million in 2025, as compared to RMB578 million in 2024. The increase was primarily due to the increase in personnel-related costs..

General and administrative expenses was RMB362 million in 2025, as compared to RMB375 million in 2024.

Change in fair value of financial guarantee derivatives and loans at fair value was a gain of RMB508 million in 2025 as compared to a loss of RMB979 million in 2024. The change was primarily driven by the fair value gains realized as a result of the release of guarantee obligation as loans are repaid, partially offset by the fair value loss from the re-measurement of the expected loss rates.

Income tax expense was RMB399 million in 2025, as compared to RMB253 million in 2024. The increase was primarily due to the increase in income before income tax expense.

Net income was RMB1,677 million in 2025, as compared to RMB1,100 million in 2024.

Recent Development

Semi-Annual Dividend

The board of directors of the Company has approved a dividend of US$0.094 per ordinary share, or US$0.188 per ADS, for the six-month period ended December 31, 2025 in accordance with the Company’s dividend policy, which is expected to be paid on June 3, 2026 to shareholders of record (including holders of ADSs) as of the close of business on April 24, 2026 New York time.

Update of Share Repurchase Program

Pursuant to the Company’s share repurchase program of up to US$50 million adopted in July 2025, the Company repurchased a total of approximately 9.6 million ADSs (equivalent to 19.2 million Class A ordinary shares) for approximately US$39 million. The remaining amount under the share repurchase program was US$11 million as of the date of this announcement. The total number of shares repurchased by the Company since the adoption of the share repurchase program amounted to approximately 5.8% of its total ordinary shares outstanding as of December 31, 2025.

In addition, Mr. Jay Wenjie Xiao has informed the Company that he has purchased a total of approximately 2.3 million ADSs (equivalent to 4.6 million Class A ordinary shares) for approximately US$10 million as of the date of announcement, after his indication to purchase up to US$10 million worth of the Company’s ADSs in July 2025.

Business Outlook

Looking ahead, while our risk metrics continue to improve, we remain prudent in light of ongoing macroeconomic uncertainties and expect total loan origination for the first quarter of 2026 to remain flat.

This forecast reflects our current preliminary views, which are subject to the impact of macroeconomic factors. The Company may adjust its performance outlook as appropriate based on evolving circumstances.

Conference Call

The Company’s management will host an earnings conference call at 7:00 AM U.S. Eastern time on March 19, 2026 (7:00 PM Beijing/Hong Kong time on March 19, 2026).

Participants who wish to join the conference call should register online at:

https://register-conf.media-server.com/register/BIa035db521c9d4308ac218dd480679390

Once registration is completed, each participant will receive the dial-in number and a unique access PIN for the conference call.

Participants joining the conference call should dial in at least 10 minutes before the scheduled start time.

A live and archived webcast of the conference call will also be available at the Company’s investor relations website at http://ir.lexin.com.

About LexinFintech Holdings Ltd.

We are a leading credit technology-empowered personal financial service enabler. Our mission is to use technology and risk management expertise to make financing more accessible for young generation consumers. We strive to achieve this mission by connecting consumers with financial institutions, where we facilitate through a unique model that includes online and offline channels, installment consumption platform, big data and AI driven credit risk management capabilities, as well as smart user and loan management systems. We also empower financial institutions by providing cutting-edge proprietary technology solutions to meet their needs of financial digital transformation.

For more information, please visit http://ir.lexin.com.

To follow us on Twitter, please go to: https://twitter.com/LexinFintech.

Use of Non-GAAP Financial Measures Statement

In evaluating our business, we consider and use adjusted net income attributable to ordinary shareholders of the Company, non-GAAP EBIT, adjusted net income per ordinary share and per ADS attributable to ordinary shareholders of the Company, four non-GAAP measures, as supplemental measures to review and assess our operating performance. The presentation of the non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with U.S. GAAP. We define adjusted net income attributable to ordinary shareholders of the Company as net income attributable to ordinary shareholders of the Company excluding share-based compensation expenses, interest expense associated with convertible notes, and investment income/(loss) and we define non-GAAP EBIT as net income excluding income tax expense, share-based compensation expenses, interest expense, net, and investment income/(loss).

We present these non-GAAP financial measures because they are used by our management to evaluate our operating performance and formulate business plans. Adjusted net income attributable to ordinary shareholders of the Company enables our management to assess our operating results without considering the impact of share-based compensation expenses, interest expense associated with convertible notes, and investment income/(loss). Non-GAAP EBIT, on the other hand, enables our management to assess our operating results without considering the impact of income tax expense, share-based compensation expenses, interest expense, net, and investment income/(loss). We also believe that the use of these non-GAAP financial measures facilitates investors’ assessment of our operating performance. These non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP.

These non-GAAP financial measures have limitations as an analytical tool. One of the key limitations of using adjusted net income attributable to ordinary shareholders of the Company and non-GAAP EBIT is that they do not reflect all items of income and expense that affect our operations. Share-based compensation expenses, interest expense associated with convertible notes, income tax expense, interest expense, net, and investment income/(loss) have been and may continue to be incurred in our business and are not reflected in the presentation of adjusted net income attributable to ordinary shareholders of the Company and non-GAAP EBIT. Further, these non-GAAP financial measures may differ from the non-GAAP financial information used by other companies, including peer companies, and therefore their comparability may be limited.

We compensate for these limitations by reconciling each of the non-GAAP financial measures to the most directly comparable U.S. GAAP financial measure, which should be considered when evaluating our performance. We encourage you to review our financial information in its entirety and not rely on a single financial measure.

Exchange Rate Information Statement

This announcement contains translations of certain RMB amounts into U.S. dollars (“US$”) at specified rates solely for the convenience of the reader. Unless otherwise stated, all translations from RMB to US$ were made at the rate of RMB6.9931 to US$1.00, the exchange rate set forth in the H.10 statistical release of the Federal Reserve Board on December 31, 2025. The Company makes no representation that the RMB or US$ amounts referred could be converted into US$ or RMB, as the case may be, at any particular rate or at all.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about Lexin’s beliefs and expectations, are forward-looking statements. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, the expectation of the collection efficiency and delinquency, business outlook and quotations from management in this announcement, contain forward-looking statements. Lexin may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Lexin’s goal and strategies; Lexin’s expansion plans; Lexin’s future business development, financial condition and results of operations; Lexin’s expectation regarding demand for, and market acceptance of, its credit and investment management products; Lexin’s expectations regarding keeping and strengthening its relationship with borrowers, institutional funding partners, merchandise suppliers and other parties it collaborates with; general economic and business conditions; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in Lexin’s filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and Lexin does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For investor and media inquiries, please contact:

LexinFintech Holdings Ltd.

IR inquiries:

Will Tan

Tel: +86 (755) 3637-8888 ext. 6258

E-mail: [email protected]

Media inquiries:

Ruifeng Xu

Tel: +86 (755) 3637-8888 ext. 6993

E-mail: [email protected]

SOURCE LexinFintech Holdings Ltd.

LexinFintech Holdings Ltd. Unaudited Condensed Consolidated Balance Sheets
	As of
(In thousands)	December 31, 2024		December 31, 2025
	RMB		RMB		US$
ASSETS
Current Assets
Cash and cash equivalents	2,254,213		2,156,133		308,323
Restricted cash	1,638,479		1,717,773		245,638
Restricted term deposit and short-term investments	138,497		78,458		11,219
Short-term financing receivables, net(1)	4,668,715		5,450,418		779,399
Short-term contract assets and receivables, net(1)	5,448,057		3,763,096		538,116
Deposits to insurance companies and guarantee companies	2,355,343		2,187,609		312,824
Prepayments and other current assets	1,321,340		2,858,054		408,696
Amounts due from related parties	61,722		84,531		12,088
Inventories, net	22,345		24,119		3,449
Total Current Assets	17,908,711		18,320,191		2,619,752
Non-current Assets
Restricted cash	100,860		91,937		13,147
Long-term financing receivables, net(1)	112,427		167,378		23,935
Long-term contract assets and receivables, net(1)	317,402		317,496		45,401
Property, equipment and software, net	613,110		895,046		127,990
Land use rights, net	862,867		828,467		118,469
Long-term investments	284,197		243,971		34,887
Deferred tax assets	1,540,842		1,763,235		252,139
Other assets	500,363		535,242		76,539
Total Non-current Assets	4,332,068		4,842,772		692,507
TOTAL ASSETS	22,240,779		23,162,963		3,312,259
LIABILITIES
Current liabilities
Accounts payable	74,443		101,178		14,468
Amounts due to related parties	10,927		8,708		1,245
Short-term borrowings and current portion of long-term borrowings	690,772		905,791		129,526
Short-term funding debts	2,754,454		2,440,685		349,013
Deferred guarantee income	975,102		1,305,911		186,743
Contingent guarantee liabilities	1,079,000		544,191		77,818
Accruals and other current liabilities	4,019,676		4,371,484		625,110
Total Current Liabilities	9,604,374		9,677,948		1,383,923
Non-current Liabilities
Long-term borrowings	585,024		566,015		80,939
Long-term funding debts	1,197,211		850,590		121,633
Deferred tax liabilities	91,380		105,212		15,045
Other long-term liabilities	22,784		10,567		1,511
Total Non-current Liabilities	1,896,399		1,532,384		219,128
TOTAL LIABILITIES	11,500,773		11,210,332		1,603,051
Shareholders’ equity:
Class A Ordinary Shares	205		209		32
Class B Ordinary Shares	41		41		7
Treasury stock	(328,764	)	(493,846	)	(70,619	)
Additional paid-in capital	3,314,866		3,396,667		485,717
Statutory reserves	1,178,309		1,260,923		180,310
Accumulated other comprehensive income	(29,559	)	(27,597	)	(3,946	)
Retained earnings	6,604,908		7,816,234		1,117,707
Total shareholders’ equity	10,740,006		11,952,631		1,709,208
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	22,240,779		23,162,963		3,312,259

___

_________________________________

(1)

Short-term financing receivables, net of allowance for credit losses of RMB102,124 and RMB198,694 as of December 31, 2024 and December 31, 2025, respectively. Short-term contract assets and receivables, net of allowance for credit losses of RMB409,590 and RMB259,054 as of December 31, 2024 and December 31, 2025, respectively. Long-term financing receivables, net of allowance for credit losses of RMB1,820 and RMB3,723 as of December 31, 2024 and December 31, 2025, respectively. Long-term contract assets and receivables, net of allowance for credit losses of RMB30,919 and RMB14,569 as of December 31, 2024 and December 31, 2025, respectively.

LexinFintech Holdings Ltd. Unaudited Condensed Consolidated Statements of Operations
	For the Three Months Ended December 31,							For the Year Ended December 31,
(In thousands, except for share and per share data)	2024		2025					2024		2025
	RMB		RMB		US$			RMB		RMB		US$
Operating revenue:
Credit facilitation service income	2,712,066		2,484,555		355,286			10,999,931		9,562,072		1,367,358
Loan facilitation and servicing fees-credit oriented	1,624,410		1,293,440		184,959			6,325,924		4,988,562		713,355
Guarantee income	577,168		684,863		97,934			2,663,824		2,423,570		346,566
Financing income	510,488		506,252		72,393			2,010,183		2,149,940		307,437
Tech-empowerment service income	601,693		170,317		24,355			1,881,376		2,081,335		297,627
Installment e-commerce platform service income	345,074		388,204		55,512			1,322,287		1,508,680		215,738
Total operating revenue	3,658,833		3,043,076		435,153			14,203,594		13,152,087		1,880,723
Operating cost
Cost of sales	(352,749	)	(248,121	)	(35,481	)		(1,319,526	)	(1,206,033	)	(172,460	)
Funding cost	(57,471	)	(34,185	)	(4,888	)		(326,451	)	(228,958	)	(32,741	)
Processing and servicing cost	(583,119	)	(632,479	)	(90,443	)		(2,291,904	)	(2,442,557	)	(349,281	)
Provision for financing receivables	(296,741	)	(250,218	)	(35,781	)		(865,524	)	(1,016,742	)	(145,392	)
Provision for contract assets and receivables	(153,968	)	(158,797	)	(22,708	)		(718,413	)	(614,364	)	(87,853	)
Provision for contingent guarantee liabilities	(940,740	)	(935,194	)	(133,731	)		(3,655,548	)	(3,174,787	)	(453,989	)
Total operating cost	(2,384,788	)	(2,258,994	)	(323,032	)		(9,177,366	)	(8,683,441	)	(1,241,716	)
Gross profit	1,274,045		784,082		112,121			5,026,228		4,468,646		639,007
Operating expenses:
Sales and marketing expenses	(464,263	)	(388,093	)	(55,497	)		(1,787,299	)	(1,918,894	)	(274,398	)
Research and development expenses	(151,081	)	(131,947	)	(18,868	)		(578,243	)	(595,316	)	(85,129	)
General and administrative expenses	(95,335	)	(69,964	)	(10,005	)		(374,481	)	(361,819	)	(51,739	)
Total operating expenses	(710,679	)	(590,004	)	(84,370	)		(2,740,023	)	(2,876,029	)	(411,266	)
Change in fair value of financial guarantee derivatives and loans at fair value	(143,619	)	79,433		11,359			(979,234	)	508,160		72,666
Interest expense, net	(2,560	)	(8,015	)	(1,146	)		(9,007	)	(22,732	)	(3,251	)
Investment loss	(543	)	(3,503	)	(501	)		(2,417	)	(21,903	)	(3,132	)
Others, net	13,754		4,014		574			58,188		19,461		2,783
Income before income tax expense	430,398		266,007		38,037			1,353,735		2,075,603		296,807
Income tax expense	(67,649	)	(51,923	)	(7,425	)		(253,275	)	(398,526	)	(56,988	)
Net income	362,749		214,084		30,612			1,100,460		1,677,077		239,819
Net income attributable to ordinary shareholders of the Company	362,749		214,084		30,612			1,100,460		1,677,077		239,819
Net income per ordinary share attributable to ordinary shareholders of the Company
Basic	1.09		0.64		0.09			3.32		4.95		0.71
Diluted	1.03		0.62		0.09			3.24		4.72		0.68
Net income per ADS attributable to ordinary shareholders of the Company
Basic	2.18		1.27		0.18			6.64		9.90		1.42
Diluted	2.06		1.24		0.18			6.49		9.45		1.35
Weighted average ordinary shares outstanding
Basic	333,182,976		336,234,641		336,234,641			331,403,936		338,943,939		338,943,939
Diluted	351,577,582		346,075,067		346,075,067			339,261,349		355,089,877		355,089,877

LexinFintech Holdings Ltd. Unaudited Condensed Consolidated Statements of Comprehensive Income
	For the Three Months Ended December 31,							For the Year Ended December 31,
(In thousands)	2024		2025					2024		2025
	RMB		RMB		US$			RMB		RMB		US$
Net income	362,749		214,084		30,612			1,100,460		1,677,077		239,819
Other comprehensive income
Foreign currency translation adjustment, net of nil tax	642		(1,297	)	(185	)		(16,014	)	1,962		281
Total comprehensive income	363,391		212,787		30,427			1,084,446		1,679,039		240,100
Total comprehensive income attributable to ordinary shareholders of the Company	363,391		212,787		30,427			1,084,446		1,679,039		240,100

LexinFintech Holdings Ltd. Unaudited Reconciliations of GAAP and Non-GAAP Results
	For the Three Months Ended December 31,						For the Year Ended December 31,
(In thousands, except for share and per share data)	2024		2025				2024		2025
	RMB		RMB		US$		RMB		RMB		US$
Reconciliation of Adjusted net income attributable to ordinary shareholders of the Company to Net income attributable to ordinary shareholders of the Company
Net income attributable to ordinary shareholders of the Company	362,749		214,084		30,612		1,100,460		1,677,077		239,819
Add: Share-based compensation expenses	27,244		21,119		3,020		94,623		96,175		13,753
Investment loss	543		3,503		501		2,417		21,903		3,132
Adjusted net income attributable to ordinary shareholders of the Company	390,536		238,706		34,133		1,203,195		1,795,155		256,704
Adjusted net income per ordinary share attributable to ordinary shareholders of the Company
Basic	1.17		0.71		0.10		3.63		5.30		0.76
Diluted	1.11		0.69		0.10		3.55		5.06		0.72
Adjusted net income per ADS attributable to ordinary shareholders of the Company
Basic	2.34		1.42		0.20		7.26		10.59		1.51
Diluted	2.22		1.38		0.20		7.09		10.11		1.45
Weighted average shares used in calculating net income per ordinary share for non-GAAP EPS
Basic	333,182,976		336,234,641		336,234,641		331,403,936		338,943,939		338,943,939
Diluted	351,577,582		346,075,067		346,075,067		339,261,349		355,089,877		355,089,877
Reconciliations of Non-GAAP EBIT to Net income
Net income	362,749		214,084		30,612		1,100,460		1,677,077		239,819
Add: Income tax expense	67,649		51,923		7,425		253,275		398,526		56,988
Share-based compensation expenses	27,244		21,119		3,020		94,623		96,175		13,753
Interest expense, net	2,560		8,015		1,146		9,007		22,732		3,251
Investment loss	543		3,503		501		2,417		21,903		3,132
Non-GAAP EBIT	460,745		298,644		42,704		1,459,782		2,216,413		316,943

Additional Credit Information

Vintage Charge Off Curve

¹

Dpd30+/GMV by Performance Windows

¹

First Payment Default 30+

¹

        1.Loans facilitated under ICP and E-commerce business are excluded from the charts.

BLACKHAWK, Calif., March 18, 2026 (GLOBE NEWSWIRE) — Vesicor Therapeutics, Inc., a San Gabriel, California-based early development stage biotechnology corporation focused on the development of p53-based cancer therapeutics delivered via precision-engineered microvesicles and a proposed de-SPAC acquisition target for Black Hawk Acquisition Corporation (Nasdaq: BKHA, BKHAU, BKHAR), today announced that its Board of Directors has appointed Michael Tolentino, M.D., an accomplished biotech leader with deep industry experience, as Chief Executive Officer (CEO), effective March 17, 2026. He succeeds Founder and CEO Luo Feng, Ph.D., who has been appointed Chief Scientific Officer.

“Dr. Tolentino is an exceptional leader whose biotech industry expertise, deep relationships across the contract research organization (CRO) and pharma ecosystems and has a proven track record of creating shareholder value is exactly what Vesicor needs in its next CEO,” stated Warren Hosseinion, M.D., Chairman of the Board of Vesicor Therapeutics. “We are honored to have Dr. Tolentino as our new CEO as we work to complete our proposed de-SPAC merger with Blackhawk Acquisition Corporation and seek to accelerate our IND-enabling studies and IND-submission to the FDA.”

“I am delighted to join Vesicor Therapeutics as CEO. I have tremendous respect and admiration for this company, its science and its Founders and I am eager to build upon the technology and work the team has been doing to position itself for an IND submission in 2027. I see significant opportunities to develop potent therapeutics against cancer and create value for our shareholders,” stated Michael Tolentino, M.D.

Dr. Tolentino is a serial entrepreneur and longtime biotechnology leader and widely respected executive with more than 20 years of experience and deep relationships across the Drug Discovery, Pre-Clinical Development, Clinical Development, and Pharmaceutical Industry. In the Laboratory of Dr. Judah Folkman, he discovered the importance of the VEGF pathway in retinal disease and cancer. While at Harvard Medical School, he helped invent and pre-clinically develop Avastin with Genentech, the drug that launched both the retinal and oncologic anti-VEGF industry. He subsequently invented and was the pre-clinical and clinical developer of Bevasiranib, the first RNA interference and siRNA drug taken to clinic for diabetic retinopathy and macular degeneration. He was the Founder and served as CEO, CSO and CMO of Acuity Pharmaceuticals, which merged to form OPKO Health in 2007.

In 2008, he was the scientific founder and consultant for Promedior, Inc., a privately held biotech company that advanced the anti-fibrotic PRM-151 for idiopathic pulmonary fibrosis and myelofibrosis. Promedior was sold to Roche in 2018 for $390 million in cash and contingent payments up to $1 billion.

He Co-founded and was a Board member of Panther Pharmaceuticals from 2018-2023. Concurrently, he was the Co-founding physician and partner of Vision Integrated Partners, a PE-funded ophthalmic roll-up where he founded, directed and incorporated a clinical trial site management organization called Blue Ocean Clinical Research that ran clinical trials with Dr. Tolentino as the principal investigator.

Dr. Tolentino Co-founded Aviceda Therapeutics, invented AVD-104 and served as CSO from 2018-2021 and CTO/CIO from 2018 until 2025, when Aviceda secured $207.5 million Series C financing. He also served on the board of the company from 2018-2024 and helped design and manage the Phase 2-3 clinical trial.

Dr. Tolentino is the Co-founder, CEO and Chairman of Avdarna Therapeutics since 2021. Avdarna is a pre-clinical to clinical developer of novel AI-generated proprietary protein/peptide therapeutics that mimic and enhance the efficacy of current blockbuster drugs like GLP-1, GIP-1, glucagon agonists, checkpoint inhibitors, targeted nucleotide therapeutic gene delivery, cancer-targeted antibodies, nanobodies and ADCs. Avdarna is the pre-clinical to clinical developer for assets generated by Aikium.

He is also the Co-founder and Chief Development Officer of Aikium, Inc. Aikium is revolutionizing therapeutics discovery and development with Yotta-ML, the world’s first proprietary 10^24 protein/peptide sequence structured data-set trained, drug discovery AI platform. The Yotta platform is taught to identify therapeutic agonists or antagonists that bind clinically validated targets such as GLP-1, GIP-1, Glucagon, and checkpoint receptors, as well as previously undruggable targets such as GPCRs, cancer associated antigens, and intracellular proteins. Aikium with Avdarna is rapidly developing novel therapeutics replacing drugs going off patent with more efficacious, longer acting, less toxic, multi-specific and oral drugs. Aikium has also identified protein binders to be developed for novel targets leading to the next-generation peptide/protein therapeutics, antibody drug conjugates, gene therapies and beyond. Cancer antigen targeted peptides discovered by Aikium can be conjugated to microvesicles and be used to specifically target cancer cells for p53 gene delivery and other cancer killing agents such as topoisomerase inhibitors, alkylating agents and microtubule inhibitors.

Dr. Tolentino holds a BA in both Computer Science and Organizational Behavior and Management from Brown University, a M.D. from the University of Massachusetts Chan School of Medicine, completed his Research Fellowships and Residency in Ophthalmology from Harvard Medical School and a Retinal Surgical Clinical Fellowship from the University of Pennsylvania. He served on the Faculty of Cellular, Molecular Biology and Gene Therapy, was a Scientist at the FM Kirby Center for Molecular Ophthalmology, and Clinical Faculty at the Scheie Eye Institute all organization at the University of Pennsylvania.

Forward Looking Statements. Any statements in this press release other than statements of historical fact are forward-looking statements. Forward-looking statements include, but are not limited to, statements about future expectations, plans and prospects for Vesicor Therapeutics, Inc. (“Vesicor”) or, for any statements attributed to Black Hawk Acquisition Corporation, a SPAC, (“BHAC”), including the development and pursuit of regulatory approval of Vesicor’s sole product candidate and, if FDA approval is obtained, commercialization of that product. Vesicor does not have FDA approval for its sole product candidate and has not commenced FDA regulatory approval process for its sole product candidate as of the date of this press release. Any other statements containing the words “believe,” “hope” “will,” “would,” “continue,” “expect,” “should,” “anticipate” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on numerous assumptions and assessments made in light of Vesicor’s experience and perception of historical trends, assumptions, predictions, current conditions, business strategies, operating environment, future developments, geopolitical factors and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Assumptions and predictions by Vesicor or by BHAC may prove to be incorrect. The various factors that could cause Vesicor’s or BHAC’s actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by forward-looking statements, include, but are not limited to: their respective financial positions and need for financing, including to fund Vesicor’s pursuit of FDA regulatory approval for its sole product candidate; the FDA regulatory review process and whether the sole product candidate will obtain FDA regulatory approval, which approval is not certain; funding and other needs for any future commercialization efforts; whether Vesicor’s sole product candidate will achieve and maintain market acceptance in a very competitive business environment characterized by rapid technological developments; Vesicor’s reliance on third-party suppliers and contractors for FDA regulatory review and, if approval is obtained, to commercially exploit Vesicor’s sole product candidate, including single-source suppliers and contractors; Vesicor’s reliance on third parties to conduct FDA clinical trials; the ability of Vesicor’s sole product candidate, if it receives FDA regulatory approval, to compete successfully with existing and new therapeutics and technologies; and Vesicor’s and any of its collaborators’ ability to protect its intellectual property and proprietary technology essential to the sole product candidate. No assurance can be given that such expectations will be realized and persons reading this communication are, therefore, cautioned not to place undue reliance on these forward-looking statements. Statements in this press release, the communication, by persons are statements of expectations and contain forward looking statements. Additional risks and information about potential impacts of financial, operational, economic, competitive, regulatory, governmental, technological, and other factors that may affect Vesicor or BHAC can be found in BHAC’s filings with the Securities and Exchange Commission concerning Vesicor, the contents of which are not incorporated by reference into, nor do they form part of, this press release. Forward-looking statements in this press release are based on information available to Vesicor, as of the date of this press release and, while Vesicor believes its assumptions or predictions are reasonable, actual results may differ materially. Subject to any obligations under applicable law, Vesicor and BHAC do not undertake any obligation to update any of their respective forward-looking statements, whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations.

Investor Contact: Warren Hosseinion, Chairman of Vesicor

Email: [email protected]

CUPERTINO, Calif., March 18, 2026 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the pricing of its previously announced public offering with healthcare focused institutional investors for the purchase and sale of 6,666,667 shares of its common stock (or common stock equivalents in lieu thereof) together with Series G warrants to purchase up to 6,666,667 shares of common stock (the “Series G Warrants”) and Series H warrants to purchase up to 6,666,667 shares of common stock (the “Series H Warrants”), at a combined offering price of $1.50 per share and accompanying warrants, for aggregate gross proceeds of approximately $10 million before deducting placement agent fees and other offering expenses.

The Series G Warrants and the Series H Warrants will have an exercise price of $1.50 per share. The Series G Warrants will be exercisable immediately and will expire five years from the issuance date. The Series H Warrants will be exercisable immediately and will expire 12 months from the issuance date.

The closing of the offering is expected to occur on or about March 20, 2026, subject to the satisfaction of customary closing conditions. The Company currently intends to use the net proceeds from the offering together with its existing cash and cash equivalents to fund research and development activities, including its planned RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia, and for working capital and other general corporate purposes.

A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.

The securities are being offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-276848), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 2, 2024, and declared effective by the SEC on February 13, 2024. A preliminary prospectus supplement related to the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and accompanying base prospectus, when available, may be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Reviva

Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

Forward-Looking Statements

This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, risks associated with the satisfaction of customary closing conditions related to the offering and uncertainties related to the closing, and use of proceeds from the proposed offering. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s final prospectus supplement to be filed with the SEC, and the documents incorporated by reference therein, including the Company’s Form 10-K for the year ended December 31, 2024 and Forms 10-Q for the quarters ended March 31, 2025, June 30, 2025 and September 30, 2025.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

REVIVA CONTACTS:

Corporate Contact:

Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com

Investor Relations Contact:

LifeSci Advisors, LLC
PJ Kelleher
[email protected]

SAN DIEGO, March 18, 2026 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Driven Brands Holdings Inc. (NASDAQ: DRVN) common stock between May 9, 2023 and February 24, 2026, inclusive (the “Class Period”), have until May 8, 2026 to seek appointment as lead plaintiff of the Driven Brands class action lawsuit. Captioned Clark v. Driven Brands Holdings Inc., No. 26-cv-01902 (S.D.N.Y.), the Driven Brands class action lawsuit charges Driven Brands as well as certain of Driven Brands’ top current and former executives with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the

Driven Brands

class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-driven-brands-holdings-class-action-lawsuit-drvn.html

You can also contact attorney

J.C. Sanchez

of Robbins Geller by calling 800/449-4900 or via e-mail at

[email protected]

.

CASE ALLEGATIONS: Driven Brands is an automotive services company.

The Driven Brands class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) there were errors relating to the recording of leases which primarily impacted the right of use assets and right of use liabilities recorded in the consolidated balance sheet as of December 28, 2024, and September 27, 2025; (ii) there were errors in reporting opening and ending cash balances and operating cash flows, which resulted in overstatements of cash and revenue and understatement of selling, general and administrative expense in consolidated statement of operations for fiscal years 2023 and 2024; and (iii) supply and other expenses were improperly presented as company-operated store expenses in fiscal years 2023 and 2024; (iv) other errors were identified relating to income tax provision, supply and other revenue, fixed assets, cloud computing, lease cash applications, balance sheet and income statement misclassifications, improperly recognized revenue in Driven Brands’ ATI business primarily related to fiscal year 2025.

The Driven Brands class action lawsuit further alleges that on February 25, 2026, Driven Brands disclosed that its Audit Committee of the Board of Directors “concluded there were material errors in our previously issued consolidated financial statements for the fiscal year ended December 28, 2024 (‘fiscal year 2024’) and the fiscal year ended December 30, 2023 (‘fiscal year 2023’) contained in the Company’s Annual Report on Form 10-K for the fiscal year 2024, and in our previously issued unaudited condensed consolidated financial statements for each of the quarterly and year-to-date periods within fiscal year 2024 as well as the quarterly and year-to-date periods for the periods ended September 27, 2025, June 28, 2025 and March 29, 2025, and concluded that such financial statements should not be relied upon and required restatement.” On this news, the price of Driven Brands common stock fell nearly 40%, according to the complaint.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Driven Brands common stock during the Class Period to seek appointment as lead plaintiff in the Driven Brands class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Driven Brands class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Driven Brands class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Driven Brands class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 
Services may be performed by attorneys in any of our offices. 

Contact:
        Robbins Geller Rudman & Dowd LLP
        J.C. Sanchez
        655 W. Broadway, Suite 1900, San Diego, CA 92101
        800-449-4900
        [email protected]

SAN DIEGO, March 18, 2026 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Trip.com Group Limited (NASDAQ: TCOM) publicly traded securities between April 30, 2024 and January 13, 2026, both dates inclusive (the “Class Period”), have until May 11, 2026 to seek appointment as lead plaintiff of the Trip.com class action lawsuit. Captioned De Wilde v. Trip.com Group Limited, No. 26-cv-01420 (E.D.N.Y.), the Trip.com class action lawsuit charges Trip.com as well as certain of Trip.com’s top executive officers with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the

Trip.com

class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-trip-com-group-limited-class-action-lawsuit-tcom.html

You can also contact attorney

J.C. Sanchez

of Robbins Geller by calling 800/449-4900 or via e-mail at

[email protected]

.

CASE ALLEGATIONS: Trip.com, through its subsidiaries, operates as a travel service provider for accommodation reservation, transportation ticketing, packaged tours, in-destination, corporate travel management, and other travel-related services.

The Trip.com class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that defendants recklessly understated the regulatory risk facing Trip.com as a result of its monopolistic business activities.

The Trip.com class action lawsuit further alleges that on January 14, 2026, Bloomberg published an article titled “China Starts Antitrust Probe of Trip.com Ahead of Travel Peak,” which stated that “China is investigating Trip.com . . . over alleged antitrust conduct, taking aim at the country’s dominant online travel platform.” The article further allegedly revealed that “[i]n September, the market regulator in Zhengzhou summoned Trip.com for violations of rules against setting ‘unfair restrictions’ on merchants’ transactions and prices.” On this news, the price of Trip.com American Depositary Shares fell approximately 19% over two trading sessions.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Trip.com publicly traded securities during the Class Period to seek appointment as lead plaintiff in the Trip.com class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Trip.com investor class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Trip.com shareholder class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Trip.com class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes. 
Services may be performed by attorneys in any of our offices. 

Contact:
        Robbins Geller Rudman & Dowd LLP
        J.C. Sanchez
        655 W. Broadway, Suite 1900, San Diego, CA 92101
        800-449-4900
        [email protected]